These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 23167833)

  • 1. Liposomal amphotericin B as a treatment for human leishmaniasis.
    Balasegaram M; Ritmeijer K; Lima MA; Burza S; Ortiz Genovese G; Milani B; Gaspani S; Potet J; Chappuis F
    Expert Opin Emerg Drugs; 2012 Dec; 17(4):493-510. PubMed ID: 23167833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia.
    Tamiru A; Tigabu B; Yifru S; Diro E; Hailu A
    BMC Infect Dis; 2016 Oct; 16(1):548. PubMed ID: 27724891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study.
    Sundar S; Pandey K; Thakur CP; Jha TK; Das VN; Verma N; Lal CS; Verma D; Alam S; Das P
    PLoS Negl Trop Dis; 2014 Sep; 8(9):e3169. PubMed ID: 25233346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging medications for the treatment of leishmaniasis.
    Chakravarty J; Sundar S
    Expert Opin Pharmacother; 2019 Jul; 20(10):1251-1265. PubMed ID: 31063412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
    Abongomera C; Diro E; de Lima Pereira A; Buyze J; Stille K; Ahmed F; van Griensven J; Ritmeijer K
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006527. PubMed ID: 29799869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
    Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
    Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
    Ritmeijer K; ter Horst R; Chane S; Aderie EM; Piening T; Collin SM; Davidson RN
    Clin Infect Dis; 2011 Dec; 53(12):e152-8. PubMed ID: 22016502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for death from visceral leishmaniasis in patients treated with liposomal amphotericin B in an endemic state in Brazil.
    Dias Tourinho B; Figueiredo Amâncio F; Lencine Ferraz M; Carneiro M
    Trans R Soc Trop Med Hyg; 2017 Apr; 111(4):163-171. PubMed ID: 28673017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India.
    Burza S; Sinha PK; Mahajan R; Lima MA; Mitra G; Verma N; Balasegaram M; Das P
    PLoS Negl Trop Dis; 2014; 8(1):e2536. PubMed ID: 24392166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
    Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
    J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure.
    Eichenberger A; Buechi AE; Neumayr A; Hatz C; Rauch A; Huguenot M; Diamantis-Karamitopoulou E; Staehelin C
    BMC Infect Dis; 2017 Jan; 17(1):81. PubMed ID: 28095796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment for human visceral leishmaniasis: a cost-effectiveness analysis for Brazil.
    de Carvalho IPSF; Peixoto HM; Romero GAS; de Oliveira MRF
    Trop Med Int Health; 2019 Sep; 24(9):1064-1077. PubMed ID: 31278808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan.
    Mueller M; Balasegaram M; Koummuki Y; Ritmeijer K; Santana MR; Davidson R
    J Antimicrob Chemother; 2006 Oct; 58(4):811-5. PubMed ID: 16916865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leishmaniasis: an update of current pharmacotherapy.
    Sundar S; Chakravarty J
    Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
    Lachaud L; Bourgeois N; Plourde M; Leprohon P; Bastien P; Ouellette M
    Clin Infect Dis; 2009 Jan; 48(2):e16-22. PubMed ID: 19093811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Royal Society of Tropical Medicine and Hygiene joint meeting with Médecins Sans Frontières at Manson House, London, 20 March 2003: field research in humanitarian medical programmes. Médecins Sans Frontières interventions against kala-azar in the Sudan, 1989-2003.
    Ritmeijer K; Davidson RN
    Trans R Soc Trop Med Hyg; 2003; 97(6):609-13. PubMed ID: 16134257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An 8-Year Retrospective Study of Human Visceral Leishmaniasis.
    Barbosa JF; de Figueiredo SM; Lyon S; Caligiorne RB
    Curr Clin Pharmacol; 2016; 11(4):265-269. PubMed ID: 27659611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of resistant visceral leishmaniasis with interferon gamma in combination with liposomal amphotericin B and allopurinol.
    Khodabandeh M; Rostami A; Borhani K; Gamble HR; Mohammadi M
    Parasitol Int; 2019 Oct; 72():101934. PubMed ID: 31129197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.